NASDAQ:ALXO - ALX Oncology Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $90.67
  • Forecasted Upside: 49.29 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$60.73
▲ +0.38 (0.63%)
1 month | 3 months | 12 months
Get New ALX Oncology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALXO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALXO

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$90.67
▲ +49.29% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for ALX Oncology in the last 3 months. The average price target is $90.67, with a high forecast of $103.00 and a low forecast of $50.00. The average price target represents a 49.29% upside from the last price of $60.73.
Buy
The current consensus among 7 investment analysts is to buy stock in ALX Oncology.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/23/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/21/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/19/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/20/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/13/2021UBS GroupInitiated CoverageBuy$96.00N/A
i
4/6/2021UBS GroupInitiated CoverageBuy$96.00Low
i
2/11/2021Credit Suisse GroupBoost Price TargetOutperform$62.00 ➝ $98.00Low
i
2/10/2021HC WainwrightInitiated CoverageBuy$100.00Low
i
Rating by S. Ramakanth at HC Wainwright
1/6/2021Cantor FitzgeraldBoost Price TargetOverweight$64.00 ➝ $103.00N/A
i
Rating by A. Young at Cantor Fitzgerald
12/15/2020Piper SandlerBoost Price TargetOverweight$78.00 ➝ $97.00Low
i
12/7/2020Piper SandlerBoost Price Target$70.00 ➝ $78.00High
i
11/18/2020Piper SandlerBoost Price TargetOverweight$55.00 ➝ $70.00Low
i
9/30/2020Lifesci CapitalReiterated RatingOutperformLow
i
Rating by A. Evertts at Lifesci Capital
8/11/2020Cantor FitzgeraldInitiated CoverageOverweightHigh
i
Rating by A. Young at Cantor Fitzgerald
8/11/2020Jefferies Financial GroupInitiated CoverageBuy$50.00High
i
8/11/2020Piper SandlerInitiated CoverageOutperform ➝ Overweight$55.00 ➝ $55.00High
i
8/11/2020Credit Suisse GroupInitiated CoverageOutperform$53.00High
i
(Data available from 4/19/2016 forward)
ALX Oncology logo
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic used for the treatment of myelodysplastic syndromes and acute myeloid leukemia, as well as a range of solid tumor indications, including head and neck squamous cell and human epidermal growth factor receptor 2 positive gastric/gastroesophageal junction carcinoma. The company was founded in 2015 and is based in Burlingame, California.
Read More

Today's Range

Now: $60.73
$59.62
$61.89

50 Day Range

MA: $71.49
$57.09
$87.68

52 Week Range

Now: $60.73
$28.01
$117.45

Volume

75,800 shs

Average Volume

239,156 shs

Market Capitalization

$2.44 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of ALX Oncology?

The following Wall Street analysts have issued reports on ALX Oncology in the last year: Cantor Fitzgerald, Credit Suisse Group AG, HC Wainwright, Jefferies Financial Group Inc., Lifesci Capital, Piper Sandler, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for ALXO.

What is the current price target for ALX Oncology?

6 Wall Street analysts have set twelve-month price targets for ALX Oncology in the last year. Their average twelve-month price target is $90.67, suggesting a possible upside of 49.3%. Cantor Fitzgerald has the highest price target set, predicting ALXO will reach $103.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $50.00 for ALX Oncology in the next year.
View the latest price targets for ALXO.

What is the current consensus analyst rating for ALX Oncology?

ALX Oncology currently has 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ALXO will outperform the market and that investors should add to their positions of ALX Oncology.
View the latest ratings for ALXO.

What other companies compete with ALX Oncology?

How do I contact ALX Oncology's investor relations team?

ALX Oncology's physical mailing address is 866 MALCOLM ROAD SUITE 100, BURLINGAME CA, 94010. The company's listed phone number is 650-466-7125 and its investor relations email address is [email protected] The official website for ALX Oncology is www.alxoncology.com.